SCHEDULE 13D/A: Yunqi Capital Opposes STAAR Surgical Merger Adjournment

Yunqi Capital and its affiliates, holding 5.1% of STAAR Surgical, publicly urged the company's board to proceed with a stockholder vote on the Proposed Merger, opposing any further adjournment or rushed sales process.

Summary

• Yunqi Path Capital Master Fund, Yunqi Capital Limited, Yunqi Capital Cayman Limited, and Christopher Min Fang Wang (collectively, "Reporting Persons") filed Amendment No. 3 to their Schedule 13D.
• The Reporting Persons beneficially own 2,500,061 shares of STAAR SURGICAL CO common stock, representing 5.1% of the class.
• On October 25, 2025 (Hong Kong time), the Reporting Persons issued a press release (Fourth Press Release) expressing opposition to the adjournment of the special meeting of stockholders.
• The press release urged STAAR SURGICAL CO to allow stockholders to vote on the Proposed Merger.
• The Reporting Persons also advised against commencing a new "go shop" period or running a rushed sales process.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative from the perspective of the company's board, as a significant shareholder group is publicly opposing their actions regarding a merger. From a shareholder advocacy perspective, it could be seen as positive, but for the company's operational and strategic execution, it represents a challenge and potential friction.

Positives

• Reporting Persons are advocating for shareholder rights by urging a direct vote on the Proposed Merger.
• The stance aims to prevent a potentially rushed sales process or a new "go shop" period that might not be in the best interest of all shareholders.

Negatives

• The filing indicates a disagreement between a significant shareholder group (5.1% stake) and the Issuer's board regarding the handling of the Proposed Merger.
• Opposition to the adjournment of the special meeting suggests potential delays or complications in the merger process.

Risks

• Potential for prolonged uncertainty regarding the Proposed Merger due to shareholder opposition.
• Risk of a "rushed sales process" if the board does not heed the Reporting Persons' call for a direct vote.
• Risk of a new "go shop" period potentially delaying the merger or introducing new complexities.

Future Outlook

The Reporting Persons' future outlook is focused on ensuring a timely stockholder vote on the Proposed Merger and preventing any actions that could undermine shareholder value, such as a rushed sales process or an unnecessary "go shop" period.

Management Comments

• The Reporting Persons issued via press release an open letter to the board of directors of the Issuer discussing the Reporting Persons' opposition to the adjournment of the special meeting of stockholders.
• The Fourth Press Release urges the Issuer to let stockholders vote on the Proposed Merger and not to commence a new 'go shop' period or run a rushed sales process.

Industry Context

This filing reflects a common scenario in corporate mergers where significant shareholders, often activist investors, challenge the board's decisions regarding the transaction process. In the medical device industry, mergers and acquisitions are frequent, and shareholder activism can play a crucial role in shaping deal terms and timelines, especially when there are concerns about valuation or process integrity.

Comparison to Industry Standards

• The 5.1% stake held by Yunqi Capital is a substantial position for an activist investor, providing a strong platform to influence corporate governance decisions, comparable to other activist campaigns seen in the medical technology sector.
• The public letter and opposition to a merger adjournment are standard tactics employed by activist investors to pressure boards, similar to actions taken by funds like Starboard Value or Elliott Management in other industries when they perceive a lack of shareholder value maximization in M&A processes.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the call for a vote on the Proposed Merger, potentially influencing the outcome and valuation of their shares.
• Management/Board: Faces pressure from a significant shareholder group regarding strategic decisions and corporate governance related to the merger.

Next Steps

• STAAR Surgical's board is urged to allow stockholders to vote on the Proposed Merger.
• The Reporting Persons advocate against a new "go shop" period or a rushed sales process.

Key Dates

Recommendation

The filing indicates significant shareholder activism regarding a proposed merger, creating uncertainty around the transaction's timeline and terms. While the activist's stance could potentially lead to a better outcome for shareholders, the immediate impact is increased friction and potential delays. Investors should hold to monitor how the board responds to this pressure and the subsequent developments in the merger process before making further investment decisions.

Keywords

STAAR Surgical, Yunqi Capital, Schedule 13D, Activist Investor, Merger, Shareholder Vote, Corporate Governance, Proxy Fight, Ophthalmology, Medical Devices